Actavis' Viberzi, Valeant's Xifaxan OK'd in IBS-D in US
This article was originally published in Scrip
Executive Summary
The FDA on 27 May approved Actavis' and Patheon Pharmaceuticals' Viberzi (eluxadoline) and Valeant's and its subsidiary Salix's Xifaxan (rifaximin) to treat adults with irritable bowel syndrome with diarrhea (IBS-D).